


Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/676.727
		Filing Date	September 30, 2003
		Confirmation Number	2946
		First Named Inventor	VERKMAN, ALAN
		Group Art Unit	1614
		Examiner Name	SPIVACK
		Attorney Docket Number	UCSF-291
Sheet	1	of	4

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
PS		4,965,155	B1	Nishiguchi et al.	10/23/1990	
PS		2002/0049211	A1	Sobolov-Jaynes et al.	04/25/2002	
PS		2002/0049214	A1	Gibbs et al.	04/25/2002	
PS		6,380,186	B1	Howard	04/30/2002	
PS		6,403,592	B1	Howard	06/11/2002	
PS		2002/0072519	A1	Howard	06/13/2002	
PS		2002/0091117	A1	Howard	07/11/2002	
PS		2002/0091118	A1	Howard	07/11/2002	
PS		2002/0091119	A1	Howard	07/11/2002	
PS		6,423,708	B1	Gibbs et al.	07/23/2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ²	Number ²	Kind Code ² (if known)				
PS- 105 PS		JP	1-156752	A	DAI NIPPON GAKKI CO., LTD.	06/20/1989		
		JP	1-173065	A	DAI NIPPON GAKKI CO., LTD.	07/07/1989		
		JP	1-172836	A	DAI NIPPON GAKKI CO., LTD.	07/07/1989		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PS		Abdel-Rahman et al., "Heterodiene Synthesis I Reaction of 5-Arylidenerhodanine Derivatives with 1-Morpholinocyclohexene Enamine", <i>Synthetic Communications</i> 19(3&4) pgs 345-354 (1989).	
PS		Abdel-Rahman et al., "A Chemical Evidence Supporting the Formation of Dihydropyran Adducts from the Reaction of 5-Arylidenerhodanines with 1-Morpholinocyclohexene through zwitterionic Intermediate", <i>Afinidad L.</i> 50(445), pgs. 155-159 (1993).	
PS		Abdel-Rahman, "Dihydropyrans form the Heterodiene Reaction of 5-Arylidenerhodanine Derivatives with Isoprene", <i>Chem Papers</i> 47(6) 385-387 (1993).	
PS		Cabantchik et al., "Chemical Probes for Anion Transporters of Mammalian Cell Membranes", <i>Invited Review The American Physiological Society</i> pgs. C803-C827 (1992).	

Examiner Signature	P. Spivack	Date Considered	2/17/06
-----------------------	------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form T449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/262,573
		Filing Date	September 30, 2002
		First Named Inventor	VERKMAN, ALAN
		Group Art Unit	1614
		Examiner Name	
Sheet	2	of	4
		Attorney Docket Number	UCSF-291

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PS		Edwards et al., "Induction of a Glibenclamide-sensitive K-current by Modification of a Delayed Rectifier Channel in Rat Portal Vein and Insulinoma Cells" Br. J. Pharmacol. 110, 1280-1281 (1993).	
PS		El-Shafel et al., "Applications of Phase-Transfer Catalysis in Reactions with Rhodanine Derivatives", Gazzetta Chimica Italiana, 120, pgs. 197-201 (1990).	
PS		Gabriel et al., "Cystic Fibrosis Heterozygote Resistance to Cholera Toxin in the Cystic Fibrosis Mouse Model", Science Volume 266, pgs 107-109 (1994).	
PS		Gabriel et al., "A Novel Plant-Derived Inhibitor of cAMP-Mediated Fluid and Chloride Secretion" The American Physiological Society pgs G58-G63 (1999).	
PS		Galletta et al., "Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds", J. Biological Chemistry Vol 276, No. 23 pp. 19723-19728 (June, 2001)	
PS		Gorbach et al., "Acute Undifferentiated Human Diarrhea in the Tropics", The Journal of Clinical Investigations" Volume 50, pp. 881-889 (1971).	
PS		Grubb et al., "Pathophysiology of Gene-Targeted Mouse Models for Cystic Fibrosis" The American Physiology Society, Physiology Reviews Vol. 79 Suppl. S193-S214 (1999).	
PS		Gupta et al., "Synthesis and Fungitoxicity of Some 5-Substituted-3-Polynitrophenyl Rhodanines", J. Indian Chem Soc. Vol LV, pp. 483-485. (1978).	
PS		Hongre et al., "Effects of Sulphonylureas on camp-Stimulated Cl- Transport Via the Cytic Fibrosis Gene Product in Human Epithelial Cells", Pflugers Arch 426: 284-287 (1994).	
PS		Jayaraman et al., "Submucosal Gland Secretions in Airways From Cystic Fibrosis Patients Have Normal [Na+] and ph But Elevated Viscosity", PNAS VO> 98 No.14 8119-8123 (July 2001).	
PS		Khalil et al., "The Action of Arlamines on 3-Aryl-5-Arylmethylenrhodanines", Revue Roumaine de Chimie 23, 6, pp. 935-941 (1978).	
PS		Khan et al., "Synthesis and Insecticidal Activity if 5-amino-7-aryl-6-cyano-3-substitute-thiazolo[4,5-b]-2,3,4,7.....", Indian Journal of Chemistry Vol. 37B pp. 1069-1074 (1998).	
PS		Ladnaya et al., "Synthesis and Properties of Thiazolidons-4 Obtained From Phenamine II. Thiasolidindions-2,4", Luov Medical Institute pp. 37-41	


Examiner Signature	<i>P. Spivack</i>	Date Considered	2/17/06
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/262,573
		Filing Date	September 30, 2002
		First Named Inventor	VERKMAN, ALAN
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	UCSF-291
Sheet	3	of	4

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
PS		Lohi et al., "Upregulation of CFTR Expression but not SLC26A3 and SLC9A3 in Ulcerative Colitis", <i>American Journal Physio Gastrointest Liver Physiology</i> 283 G587-G575 (2002).	
PS		Makhoul et al., "New Antimicrobial Rhodanines" <i>Pharmazie</i> . 51, 430-431 (1996).	
PS		McDonough et al., "Novel Pore-Lining Residues in CFTR That Govern Permeation and Open-Channel Block", <i>Neuron</i> Volume 13, pgs 623-634 (September, 1994).	
PS		Noone et al., "CFTR-Oopathies: Disease Phenotypes Associated with Cystic Fibrosis Transmembrane Regulator Gene Mutations" <i>Respir Res.</i> 2:328-332 (2001).	
PS		Oi et al., "Identification in Traditional herbal Medications and Confirmation by Synthesis of Factors that Inhibit Cholera Toxin-Induced Fluid Accumulation", <i>PNAS</i> Vol. 99 No. 5 3042-3046 (March, 2002).	
PS		Omar et al., "The Role of Substituents at Position 03 on the Mode of Cleavage of 5-Arylmethylene-2, 4-dioxothiazolidines", <i>Journal f. prakt. Chemie.</i> Band 331, Heft 3, 1989, S393-S398 (1989).	
PS		Pilewski et al., "Role of CFTR in Airway Disease" <i>Physiological Reviews</i> Vol 79, Suppl No.1, pgs. S215-S255 (January, 1999).	
PS		Rabe et al., "Cl- Channel Inhibition by Glibenclamide is Not Specific for the CFTR-type Cl- Channel", <i>Pflügers Arch-Eur J. Physiol</i> 429: 659-662 (1995).	
PS		Rasola et al., "Volume-Sensitive Chloride Currents in Four Epithelial Cell Lines Are Not Directly Correlated to the Expression of the MDR-1 Gene", <i>The J. Biol Chem.</i> Vol. 269, No.2 pp. 1432-1436 (Jan. 1994).	
PS		Richardson et al., "Studies on the Genetic and Cellular Control of Sensitivity to Enterotoxins in the Sealed Adult Mouse Model", <i>Infection and Immunity</i> Vol. 54, No. 2, pp. 522-528 (Nov. 1986).	
PS		Schultz et al., "Pharmacology of CFTR Chloride Channel Activity", <i>Physiological Reviews</i> Vol 79, Suppl No.1, pgs. S109-S144 (January, 1999).	
PS		Sheppard et al., "Effect of ATP-sensitive K+ Channel regulators on Cystic Fibrosis Transmembrane Conductance Regulator Chloride Currents", <i>J. Gen Physiol.</i> Pp. 573-591 (October 1992).	
PS		Tejchman et al., "Introduction of Selenium to Heterocyclic Compounds. Part VII. Synthesis of 3-Alkyl-5-5-benzylidene- and", <i>Polish j. Chem.</i> , 73, 1315-1322 (1999).	


Examiner Signature	P. Spivack	Date Considered	2/17/06
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Unique citation designation number. †Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/262,573
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	September 30, 2002
		First Named Inventor	VERKMAN, ALAN
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	UCSF-291
Sheet	4	of	4

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and state, country, where published	T ²
PS		Tejchman et al., "Introduction of Selenium to Heterocyclic Compounds. Part VI. Synthesis of 3-Aryl-5-benzylidene- and", Polish J. Chem., 70, 1124-1134 (1996).	
PS		Tiwari et al., "Synthesis and Fungicidal Activity of Some 3,7-diaryl-6-cyanorhodanino[4,5-b]pyridin-5.....", Indian Journal of Chemistry Vol. 28B pp. 796-798 (1989).	
PS		Wong et al., "CFTR Gene and Male Fertility", Molecular Human Reproduction Vol. 4, No. 2 pp. 107-110 (1998).	
PS		Yadav et al., "Synthesis and Fungitoxicity of Rationally Designed Thiazolo-1,3-dithiins, -thiazines, and oxathiins" J. Agric. Food Chem 40, pp. 1214-126 (1992).	
PS		Yamada et al., "Dai-2-bu", Utsunomiya Daigaku Kyoikugakubu Kiyo, 34:33-41 (1983).	
PS		Yamazaki et al., "Inhibitory Effects of Glibenclamide on Cystic Fibrosis Transmembrane Regulator, Swelling-Activated, and Ca ²⁺ -Activated Cl- Channels in Mammalian Cardiac Myocytes" Circulation Research Vo. 81(1) pp. 101-109. (July 1997).	
PS		Appendix C - Thiazolidinone Chemical Structure Search (Identified References) Pages 1-70 (2002).	

Examiner Signature	P. Spwack	Date Considered	2/17/06
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

EXPRESS MAIL LABEL NO. EV 333997817 US

Substitute for form 1449B/PTO		Complete if Known			
		Application Number	10/676,727		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Filing Date	September 30, 2003		
		First Named Inventor	VERKMAN, ALAN		
		Group Art Unit	1614		
		Examiner Name	SPIVACK		
Sheet	1	of	1	Attorney Docket Number	UCSF-291

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
B		Memorandum Regarding Compound Collections, Dated May 15, 2003	

Examiner Signature	P. Spivack	Date Considered	2/17/06
-----------------------	------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/676,727		
		Filing Date	September 30, 2003		
		First Named Inventor	VERKMAN, ALAN		
		Art Unit	1614		
		Examiner Name	Not Assigned SPIVACK		
Sheet	1	of	1	Attorney Docket Number	JCSF-291

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code* (if known)				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.†	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code*-Number*-Kind Code* (if known)					

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
PS		Database HCAPLUS on STN Online, No. 2002:932809, MA et al., "Thiazolidinone CFTR Inhibitor Identified by High-Throughput Screening Blocks Cholera Toxin-Induced Intestinal Fluid Secretion," abstract, Journal of Clinical Investigation, 2002, Vol. 110, No. 11, pages 1651-1658, (Abstract).	
PS		Database HCAPLUS on STN Online, No. 1978:597389, GUPTA et al. "Synthesis and Fungitoxicity of some 5-substituted 3-poly (nitrophenyl) rhodanines," abstract, Journal of the Indian Chemistry Society, 1978, vol. 55, No. 5, pages 483-5, (Abstract).	
PS		Database HCAPLUS on STN Online, No. 2002:664146, ROMAN et al. "Synthesis and Antiinflammatory Activity of 3-aryl-5-arylidene-thioxothiazolidine-4-ones," abstract, Framatsevtichnii Zhurnal (Kiev), 2002, Vol. 3, pages 56-59, (Abstract).	

Examiner Signature	P. Spivack	Date Considered	2/17/06
-----------------------	------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.